Company appoints healthcare technology industry veterans

Nupura Kolwalkar as chief product officer and Bill Madigan as chief commercial officer

DNAnexus Strengthens Leadership Team to Drive Ongoing Product Innovation and Commercial Growth

Media Contact:
Andrew Noble
415-722-2129
andrew@bioscribe.com

DNAnexus, Inc., provider of the leading enterprise platform for precision health data, today announced the appointment of Nupura Kolwalkar as chief product officer and Bill Madigan as chief commercial officer. The two industry veterans bring decades of experience driving revenue growth and product innovation for leading healthcare technology companies.

“I’m pleased to welcome both Nupura and Bill to the DNAnexus leadership team. They are proven industry leaders with successful track records of managing cross-functional teams and scaling business operations for emerging healthcare software and data analytics providers,” said Thomas Laur, CEO at DNAnexus. “Their insights and expertise will help guide our long-term product and commercial strategies so that we can continue to make precision health a reality for all.”

Ms. Kolwalkar is highly regarded in the healthcare industry for her expertise in identifying and addressing unmet market needs through cutting-edge data, technology, and AI solutions. During the past 20 years, she has consistently guided organizations to conceptualize, develop, and deliver high-value products that deeply resonate with customers. Previously, she held executive positions at McKesson, Brightree, ResMed, Datavant, Sharecare, NextGen Healthcare Information Systems, and Pfizer. Ms. Kolwalkar holds a master of science degree in computer science from Auburn University and a master of arts degree in industrial statistics and econometrics from Savitribai Phule Pune University in India.

Mr. Madigan brings more than two decades of experience spanning product development, client services, sales, marketing, and channel-partner development in the healthcare and life sciences industries. Previously, he was the chief revenue officer at Komodo Health, an emerging AI-powered healthcare technology provider. Before that, he held several leadership roles across Optum’s healthcare and life sciences business units, including senior director for Optum Life Sciences and head of provider analytics. In these positions, he expanded the company’s collaborations with the top 20 global pharmaceutical companies and drove revenue growth in the provider analytics business. Mr. Madigan holds a master’s degree in business, technology, and finance from the D'Amore-McKim School of Business at Northeastern University.

“This is a great time to join DNAnexus as the company looks to strengthen its leadership position and enable more customers to accelerate scientific discovery, securely collaborate across the healthcare continuum, and, ultimately, unlock insights that improve patient lives,” said Mr. Madigan. “I look forward to working with this talented team and advancing efforts to scale commercial strategies and position the company for long-term growth.”

Today, DNAnexus has more than 45,000 registered users across 48 countries and actively manages more than 105 petabytes of complex clinical genomic, proteomic, and other multi-omic datasets on behalf of a growing network of collaborators. Its comprehensive enterprise platform for precision health data meets the most rigorous industry standards for data quality, security, privacy, and regulatory compliance.

About DNAnexus

DNAnexus, the enterprise platform for precision health data, is on a mission to accelerate the development, approval, and delivery of personalized treatments. Building on more than 15 years of bioinformatics innovation and genomics expertise, DNAnexus powers a connected data ecosystem trusted by the world’s precision health leaders. This flexible ecosystem makes omics and real-world data accessible, actionable, and secure while unlocking insights that improve patient lives. For more information, visit www.dnanexus.com or follow @DNAnexus on social media.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241022997547/en/